RYVU Therapeutics S.A. Logo

RYVU Therapeutics S.A.

RVU | WAR

Overview

Corporate Details

ISIN(s):
PLSELVT00013 (+2 more)
LEI:
2594003WO9Q9HHAFL031
Country:
Poland
Address:
Kraków Leona Henryka Sternbacha 2, 30-394 Kraków
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. The company's mission is to develop innovative cancer treatments by targeting key biological pathways, including kinase, synthetic lethality, and immuno-oncology. Its pipeline features multiple candidates advancing through preclinical and clinical stages, such as RVU120 for hematological malignancies and myelofibrosis, and Dapolsertib for lymphoma. Founded in 2007 (formerly as Selvita S.A.), Ryvu leverages its scientific expertise to create precise therapies aimed at improving patient outcomes and quality of life.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for RYVU Therapeutics S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-26 15:56
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
English 2.2 KB
2025-06-26 15:56
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
Polish 1.5 KB
2025-06-26 15:50
Post-Annual General Meeting Information
Uchwaly ZWZ_2025
Polish 161.9 KB
2025-06-26 15:50
Declaration of Voting Results & Voting Rights Announcements
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Ryvu Therapeutics S.A…
English 1.4 KB
2025-06-26 15:50
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Ryvu Therapeutics S.A…
Polish 875 bytes
2025-06-20 10:29
Director's Dealing
Powiadomienie_Justyna_Żółtek
Polish 83.7 KB
2025-06-20 10:29
Share Issue/Capital Change
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce w związku z reali…
English 1.2 KB
2025-06-20 10:29
Director's Dealing
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce w związku z reali…
Polish 671 bytes
2025-06-18 20:43
Major Shareholding Notification
Notyfikacja_Tadeusz Wesołowski
Polish 93.5 KB
2025-06-18 20:43
Major Shareholding Notification
Otrzymanie zawiadomienia w trybie art. 69 OfertPublU / Receipt of notification …
English 1.6 KB
2025-06-18 20:43
Declaration of Voting Results & Voting Rights Announcements
Otrzymanie zawiadomienia w trybie art. 69 OfertPublU / Receipt of notification …
Polish 1.1 KB
2025-06-18 19:48
Director's Dealing
Notyfikacja_Fundacja_Rodzinna_Rodziny_Wesołowskich
Polish 8.0 KB
2025-06-18 19:48
Director's Dealing
Notyfikacja_Augebit
Polish 8.0 KB
2025-06-18 19:48
Major Shareholding Notification
Zawiadomienia od osób blisko związanych z osobą pełniącą obowiązki zarządcze w …
English 1.4 KB
2025-06-18 19:48
Major Shareholding Notification
Zawiadomienia od osób blisko związanych z osobą pełniącą obowiązki zarządcze w …
Polish 850 bytes

Automate Your Workflow. Get a real-time feed of all RYVU Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RYVU Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN